Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

744
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
744
Standards of Care II01:19

Standards of Care II

1.2K
Nurses bear specific legal responsibilities under several federal statutes, including:
1.2K
Cancer Therapies02:49

Cancer Therapies

10.3K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.3K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

691
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
691
Standards of Care I01:22

Standards of Care I

1.2K
Federal statutes profoundly impact nursing practice, providing critical guidelines to ensure patient care is equitable, accessible, and of the highest quality. The following laws address distinct aspects of healthcare provision and patient rights:
1.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Poor Diet and Oral Cavity Cancer Risk in Smoking and Non-Smoking Men and Women: An Analysis of Three US Cohorts.

Head & neck·2026
Same author

QIM26-313: Improving Molecular Testing Rates in Advanced Thyroid Cancer Through a Standardized Testing Pathway.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

QIM26-313: Improving Molecular Testing Rates in Advanced Thyroid Cancer Through a Standardized Testing Pathway.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Therapeutic scheduling of WEE1 inhibition preserves T cell function and promotes immune control of HPV<sup>+</sup> tumors.

bioRxiv : the preprint server for biology·2026
Same author

ASO Visual Abstract: Key Updates on the Version 9 AJCC/UICC Staging System for Salivary Gland Carcinoma.

Annals of surgical oncology·2026
Same author

Quality of Life in Patients With p16+ Oropharyngeal Cancer Receiving Accelerated Radiation Therapy With Either Cisplatin or Cetuximab in the NRG/RTOG 1016 Randomized Controlled Trial.

International journal of radiation oncology, biology, physics·2026

Related Experiment Video

Updated: Feb 27, 2026

Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine
05:39

Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine

Published on: April 5, 2024

1.3K

Current and emerging standards of concomitant chemoradiotherapy.

David J Adelstein1, Cristina P Rodriguez

  • 1Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, OH 44195, USA. adelstd@ccf.org

Seminars in Oncology
|June 12, 2008
PubMed
Summary

Combining chemotherapy with radiation therapy is the most effective treatment for advanced head and neck cancers, improving survival and local control. This approach is now standard care for specific patient groups.

More Related Videos

Irradiator Commissioning and Dosimetry for Assessment of LQ &#945; and &#946; Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.8K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

21.2K

Related Experiment Videos

Last Updated: Feb 27, 2026

Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine
05:39

Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine

Published on: April 5, 2024

1.3K
Irradiator Commissioning and Dosimetry for Assessment of LQ &#945; and &#946; Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.8K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

21.2K

Area of Science:

  • Oncology
  • Radiation Oncology
  • Head and Neck Cancer Research

Background:

  • Integrating chemotherapy into non-operative management for squamous cell head and neck cancer is crucial.
  • Chemoradiation has shown superior outcomes compared to radiation alone.

Purpose of the Study:

  • To evaluate the efficacy of combined chemotherapy and radiation in head and neck cancers.
  • To establish the standard of care for advanced, unresectable, and high-risk head and neck cancers.

Main Methods:

  • Phase III randomized trials and meta-analyses were reviewed.
  • High-dose single-agent cisplatin with concurrent radiation therapy was investigated.

Main Results:

  • Concomitant chemotherapy and radiation therapy demonstrated significant locoregional control and survival benefits.
  • This regimen is the standard of care for advanced nasopharynx cancer, unresectable tumors, and as adjuvant therapy for high-risk features.
  • It is also effective for larynx preservation.

Conclusions:

  • Chemoradiation, particularly with cisplatin, is the most effective multi-modality treatment for head and neck squamous cell carcinoma.
  • Future research will focus on optimizing schedules, targeted agents, metastasis management, toxicity reduction, and patient selection.